1400W is a slow, tight binding, and highly selective inhibitor of inducible nitric-oxide synthase in vitro and in vivo

被引:754
作者
Garvey, EP
Oplinger, JA
Furfine, ES
Kiff, RJ
Laszlo, F
Whittle, BJR
Knowles, RG
机构
[1] GLAXO WELLCOME INC, DIV MED CHEM, RES TRIANGLE PK, NC 27709 USA
[2] GLAXO WELLCOME RES & DEV LTD, DEPT PHARMACOL, BECKENHAM BR3 3BS, KENT, ENGLAND
关键词
D O I
10.1074/jbc.272.8.4959
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
N-(3-(Aminomethyl)benzyl)acetamidine (1400W) was a slow, tight binding inhibitor of human inducible nitric-oxide synthase (iNOS), The slow onset of inhibition by 1400W showed saturation kinetics with a maximal rate constant of 0.028 s(-1) and a binding constant of 2.0 mu M. Inhibition was dependent on the cofactor NADPH. L-Arginine was a competitive inhibitor of 1400W binding with a K-s value of 3.0 mu M Inhibited enzyme did not recover activity after 2 h. Thus, 1400W was either an irreversible inhibitor or an extremely slowly reversible inhibitor of human iNOS with a K-d value less than or equal to 7 nM. In contrast, inhibition of human neuronal NOS and endothelial NOS (eNOS) was relatively weaker, rapidly reversible, and competitive with L-arginine, with Ri values of 2 mu M and 50 mu M, respectively, Thus, 1400W was at least 5000-fold selective for MOS versus eNOS. This selectivity was similar to that observed in rat aortic rings, in which 1400W was greater than 1000-fold more potent against rat iNOS than eNOS. Finally, 1400W was greater than 50-fold more potent against iNOS than eNOS in a rat model of endotoxin-induced vascular injury. Thus, the potency and selectivity of 1400W inhibition of iNOS both in vitro and in vivo were far greater than of any previously described iNOS inhibitor.
引用
收藏
页码:4959 / 4963
页数:5
相关论文
共 29 条
[1]  
BAEK KJ, 1993, J BIOL CHEM, V268, P21120
[2]   SUPPRESSION OF ADJUVANT-INDUCED ARTHRITIS BY SELECTIVE-INHIBITION OF INDUCIBLE NITRIC-OXIDE SYNTHASE [J].
CONNOR, JR ;
MANNING, PT ;
SETTLE, SL ;
MOORE, WM ;
JEROME, GM ;
WEBBER, RK ;
TJOENG, FS ;
CURRIE, MG .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 273 (1-2) :15-24
[3]  
DUSHAK VG, 1968, FARMAKOL TOKSIKOL, V4, P62
[4]  
FASTIER FN, 1962, PHARMACOL REV, V14, P37
[5]  
FURFINE ES, 1994, J BIOL CHEM, V269, P26677
[6]   SELECTIVE-INHIBITION OF CONSTITUTIVE NITRIC-OXIDE SYNTHASE BY L-N(G)-NITROARGININE [J].
FURFINE, ES ;
HARMON, MF ;
PAITH, JE ;
GARVEY, EP .
BIOCHEMISTRY, 1993, 32 (33) :8512-8517
[7]   PURIFICATION AND CHARACTERIZATION OF THE CONSTITUTIVE NITRIC-OXIDE SYNTHASE FROM HUMAN PLACENTA [J].
GARVEY, EP ;
TUTTLE, JV ;
COVINGTON, K ;
MERRILL, BM ;
WOOD, ER ;
BAYLIS, SA ;
CHARLES, IG .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1994, 311 (02) :235-241
[8]  
GARVEY EP, 1994, J BIOL CHEM, V269, P26669
[9]  
Garvey EP, 1996, METHOD ENZYMOL, V268, P339
[10]   NITRIC-OXIDE - PATHOPHYSIOLOGICAL MECHANISMS [J].
GROSS, SS ;
WOLIN, MS .
ANNUAL REVIEW OF PHYSIOLOGY, 1995, 57 :737-769